CRSP Stock Overview
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
CRISPR Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$56.34|
|52 Week High||US$169.76|
|52 Week Low||US$42.51|
|1 Month Change||1.46%|
|3 Month Change||-3.35%|
|1 Year Change||-51.25%|
|3 Year Change||52.27%|
|5 Year Change||274.60%|
|Change since IPO||299.86%|
Recent News & Updates
|CRSP||US Biotechs||US Market|
Return vs Industry: CRSP underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: CRSP underperformed the US Market which returned -12.9% over the past year.
|CRSP Average Weekly Movement||11.1%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: CRSP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: CRSP's weekly volatility (11%) has been stable over the past year.
About the Company
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
CRISPR Therapeutics Fundamentals Summary
|CRSP fundamental statistics|
Is CRSP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CRSP income statement (TTM)|
|Cost of Revenue||US$496.96m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||4.02|
|Net Profit Margin||34.04%|
How did CRSP perform over the long term?See historical performance and comparison
Is CRISPR Therapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CRSP ($56.34) is trading above our estimate of fair value ($0.85)
Significantly Below Fair Value: CRSP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CRSP is good value based on its PE Ratio (14x) compared to the US Biotechs industry average (15.1x).
PE vs Market: CRSP is good value based on its PE Ratio (14x) compared to the US market (15.3x).
Price to Earnings Growth Ratio
PEG Ratio: CRSP is good value based on its PEG Ratio (0.2x)
Price to Book Ratio
PB vs Industry: CRSP is overvalued based on its PB Ratio (1.9x) compared to the US Biotechs industry average (1.5x).
How is CRISPR Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRSP's forecast earnings growth (57.9% per year) is above the savings rate (1.9%).
Earnings vs Market: CRSP's earnings (57.9% per year) are forecast to grow faster than the US market (12.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CRSP's revenue (52.7% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: CRSP's revenue (52.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRSP is forecast to be unprofitable in 3 years.
How has CRISPR Therapeutics performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRSP has high quality earnings.
Growing Profit Margin: CRSP became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CRSP has become profitable over the past 5 years, growing earnings by 36.4% per year.
Accelerating Growth: CRSP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CRSP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: CRSP's Return on Equity (13.9%) is considered low.
How is CRISPR Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: CRSP's short term assets ($2.3B) exceed its short term liabilities ($113.7M).
Long Term Liabilities: CRSP's short term assets ($2.3B) exceed its long term liabilities ($247.6M).
Debt to Equity History and Analysis
Debt Level: CRSP is debt free.
Reducing Debt: CRSP had no debt 5 years ago.
Debt Coverage: CRSP has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CRSP has no debt, therefore coverage of interest payments is not a concern.
What is CRISPR Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRSP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRSP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRSP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRSP's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CRSP has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sam Kulkarni (42 yo)
Dr. Samarth Kulkarni, Ph D., also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as Independent Director of Centessa Pharmaceuticals Lim...
CEO Compensation Analysis
Compensation vs Market: Sam's total compensation ($USD17.04M) is above average for companies of similar size in the US market ($USD6.86M).
Compensation vs Earnings: Sam's compensation has been consistent with company performance over the past year.
Experienced Management: CRSP's management team is considered experienced (3.5 years average tenure).
Experienced Board: CRSP's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.
CRISPR Therapeutics AG's employee growth, exchange listings and data sources
- Name: CRISPR Therapeutics AG
- Ticker: CRSP
- Exchange: NasdaqGM
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$4.364b
- Shares outstanding: 77.46m
- Website: https://www.crisprtx.com
Number of Employees
- CRISPR Therapeutics AG
- Baarerstrasse 14
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.